Vermillion, Inc. (VRML) financial statements (2020 and earlier)

Company profile

Business Address 12117 BEE CAVES ROAD BUILDING THREE
AUSTIN, TX 78738
State of Incorp. DE
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments  65192330
Cash and cash equivalents  65192330
Receivables 100000
Inventory, net of allowances, customer advances and progress billings 0000 
Inventory 0000  
Other undisclosed current assets 1000110
Total current assets: 1166192430
Noncurrent Assets
Property, plant and equipment 112210
Other noncurrent assets 00    
Other undisclosed noncurrent assets    0  
Total noncurrent assets: 112210
TOTAL ASSETS: 1178212431
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 322332
Accounts payable 111111
Accrued liabilities 221221
Taxes payable     00
Debt 000 11
Deferred revenue and credits   01
Other liabilities  000  
Other undisclosed current liabilities     (0)(0)
Total current liabilities: 333354
Noncurrent Liabilities
Long-term debt and lease obligation 1120  
Long-term debt, excluding current maturities 112   
Capital lease obligations   0  
Liabilities, other than long-term debt   0  0
Deferred revenue and credits    0
Other liabilities   0   
Total noncurrent liabilities: 1120 0
Total liabilities: 444354
Stockholders' equity
Stockholders' equity attributable to parent 734181927
Common stock 000000
Additional paid in capital 414399389388371359
Accumulated deficit (407)(396)(386)(371)(351)(332)
Total stockholders' equity: 734181927
TOTAL LIABILITIES AND EQUITY: 1178212431

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 333233
Revenue, net33233
Cost of revenue
(Cost of Goods and Services Sold)
 (3)(3)(3)(2)(1)(0)
Gross profit: (0)0(0)(0)12
Operating expenses (11)(11)(15)(19)(21)(11)
Operating loss: (11)(10)(15)(19)(19)(9)
Nonoperating income (expense) (0)(0)00(0)0
Investment income, nonoperating    0  
Other nonoperating expense (0)(0)    
Interest and debt expense    0  
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes    (0)00
Net loss: (11)(10)(15)(19)(19)(9)
Other undisclosed net loss attributable to parent (0)(0)(0)   
Net loss attributable to parent: (11)(10)(15)(19)(19)(9)
Undistributed earnings (loss) allocated to participating securities, basic  (1)
Net loss available to common stockholders, diluted: (11)(11)(15)(19)(19)(9)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (11)(10)(15)(19)(19)(9)
Comprehensive loss, net of tax, attributable to parent: (11)(10)(15)(19)(19)(9)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: